Kobayashi Pharmaceutical Co (4967) AI Stock Analysis

• Market Cap: ¥390.25B
• Dividend Yield: 1.67%
• Average Volume (3M): 329.46K
• Price to Earnings (P/E): 36.5
• Beta (1Y): 0.31
• Revenue Growth: -8.36%
• EPS Growth: -38.35%
• Country: JP
• Employees: 3,615
• Sector: Healthcare
• Sector Strength: 39
• Industry: Household & Personal Products
• EPS (TTM): 21.86
• Shares Outstanding: 78,050,000
• 10 Day Avg. Volume: 352,970
• 30 Day Avg. Volume: 329,456
• PEG Ratio: 5.87
• Price to Book (P/B): 1.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥5,096.79
• Price Target Upside: -5.49% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 60 Neutral
• Price Target: ¥5,663.00 ▲(5.01%Upside)

Kobayashi Pharmaceutical's stock score is primarily influenced by its stable financial position and low debt levels, despite challenges in revenue growth and profitability. Technical indicators suggest mixed signals with short-term weakness. Valuation concerns due to a high P/E ratio weigh on the overall score.

Kobayashi Pharmaceutical Co Business Overview & Revenue Model

Company Description

Kobayashi Pharmaceutical Co., Ltd. (TSE: 4967) is a leading Japanese company specializing in the development, manufacturing, and marketing of consumer healthcare products, pharmaceuticals, and medical devices. Established in 1919, the company operates in several sectors including over-the-counter (OTC) health products, household products, and medical devices. Kobayashi Pharmaceutical is renowned for its innovative approach to product development, with a diverse portfolio that includes pain relief products, gastrointestinal medications, sanitary products, and home care solutions.

How the Company Makes Money

Kobayashi Pharmaceutical Co. generates revenue through the sale of its diverse range of products across multiple categories. The company's primary revenue streams are derived from its healthcare and household product segments. In the healthcare segment, Kobayashi offers OTC medications, supplements, and medical devices, which provide consistent revenue from consumer purchases. The household products segment includes a variety of personal care and home maintenance products, which contribute significantly to the company's total earnings. Additionally, the company benefits from strategic partnerships and distribution agreements that expand its market reach both domestically and internationally. Kobayashi Pharmaceutical leverages its strong brand reputation and continuous innovation to maintain a competitive edge and ensure steady revenue growth.

Kobayashi Pharmaceutical Co Financial Statement Overview

Summary

Kobayashi Pharmaceutical exhibits strong financial stability with a low debt-to-equity ratio and robust equity ratio. However, challenges are evident in declining net profit margins and negative free cash flow, indicating areas needing improvement for sustainable growth.

Income Statement

Kobayashi Pharmaceutical has demonstrated stable revenue generation with a moderate gross profit margin of around 53% for 2024. However, there is a notable decline in net profit margin from 11.7% in 2023 to 6.1% in 2024, indicating pressure on profitability. The revenue growth rate was negative at -4.53% from 2023 to 2024, signaling a contraction. EBIT and EBITDA margins are reasonably healthy but show slight declines, reflecting increased operational challenges.

Balance Sheet

The company maintains a strong balance sheet with a very low debt-to-equity ratio of 0.004, reflecting minimal leverage risk. The equity ratio remains robust at approximately 80.4%, indicating strong financial stability and shareholder equity. Return on equity (ROE) has decreased to 4.7% in 2024, reflecting reduced net income relative to equity.

Cash Flow

Free cash flow has turned negative in 2024, a significant drop from the positive free cash flow of 4.79 billion yen in 2023, signaling cash flow challenges. The operating cash flow to net income ratio remains positive, indicating that operating activities are still generating sufficient cash relative to net income, but free cash flow to net income ratio is negative, highlighting concerns over capital expenditures.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	165.60B	173.46B	166.26B	155.25B	150.51B
Gross Profit	87.60B	96.38B	92.33B	88.77B	85.27B
EBITDA	32.73B	33.65B	31.86B	30.79B	29.91B
Net Income	10.07B	20.34B	20.02B	19.71B	19.20B
Balance Sheet
Total Assets	265.37B	267.47B	255.83B	252.55B	238.37B
Cash, Cash Equivalents and Short-Term Investments	65.75B	79.84B	104.53B	109.05B	94.34B
Total Debt	846.00M	987.00M	792.00M	630.00M	688.00M
Total Liabilities	51.90B	62.66B	57.93B	56.95B	55.78B
Stockholders Equity	213.47B	204.82B	197.90B	195.60B	182.58B
Cash Flow
Free Cash Flow	-14.81B	4.79B	15.69B	18.23B	19.84B
Operating Cash Flow	11.25B	18.36B	31.91B	22.42B	23.99B
Investing Cash Flow	-18.41B	-19.58B	-14.31B	7.99B	-12.66B
Financing Cash Flow	-7.77B	-19.46B	-20.76B	-10.38B	-6.02B

Kobayashi Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5393.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4967, the sentiment is Negative. The current price of 5393 is below the 20-day moving average (MA) of 5430.43, above the 50-day MA of 5317.33, and below the 200-day MA of 5549.71, indicating a bearish trend. The MACD of -5.35 indicates Positive momentum. The RSI at 41.25 is Neutral, neither overbought nor oversold. The STOCH value of 15.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4967.

Kobayashi Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8283	73 Outperform	$250.42B	10.97	7.98%	2.74%	3.14%	11.57%
4527	69 Neutral	$479.29B	15.17	12.05%	1.93%	13.95%	0.37%
4927	66 Neutral	$279.63B	37.44	4.49%	3.32%	-0.74%	-25.66%
Sector *	64 Neutral	¥342.56B	10.47	-2.86%	2.57%	11.81%	-7.17%
4922	64 Neutral	$336.71B	57.48	2.08%	2.37%	4.63%	-60.17%
4967	60 Neutral	¥390.25B	36.51	5.17%	1.67%	-8.36%	-38.35%
4912	59 Neutral	¥401.54B	18.87	7.58%	2.03%	2.30%	33.87%